Context Therapeutics (NASDAQ:CNTX) Announces Earnings Results, Beats Estimates By $0.03 EPS

Context Therapeutics (NASDAQ:CNTX) announced its earnings results on Tuesday. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03, FiscalAI reports.

Context Therapeutics Stock Performance

CNTX opened at $0.19 on Wednesday. The stock has a fifty day moving average of $0.29 and a 200-day moving average of $1.40. Context Therapeutics has a 12-month low of $0.18 and a 12-month high of $3.62.

Analyst Ratings Changes

CNTX has been the subject of a number of research analyst reports. Weiss Ratings raised shares of Context Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, October 15th. Lifesci Capital lowered shares of Context Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. Zacks Research cut Context Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday, October 12th. Citigroup restated an “outperform” rating on shares of Context Therapeutics in a research report on Thursday, August 6th. Finally, Wall Street Zen lowered Context Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Monday, July 20th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Context Therapeutics has an average rating of “Hold” and an average price target of $6.40.

Context Therapeutics Company Profile

Context Therapeutics Inc. (NASDAQ:CNTX) is a clinical-stage biotechnology company focused on developing targeted immunotherapies for solid tumors. The company’s approach is centered on T-cell-engaging bispecific antibodies, which are designed to direct the body’s immune cells toward cancer cells expressing specific tumor-associated antigens. Context’s lead program is CTIM-76, an investigational bispecific antibody that targets Claudin 6 (CLDN6) on tumor cells and CD3 on T cells. The program is being developed for patients with CLDN6-positive advanced solid tumors, including ovarian, endometrial, testicular and other cancers.